A study in Chiropractic & Manual Therapies finds that patients with lower back pain (LBP) may suffer from multimorbidity and poorer recovery. The authors suggest chiropractors to view LBP as a part of a disease complex rather than an isolated condition.
Frequencies of demographic variables at baseline were grouped by intensity of LBP and compared using Chi-squared tests. To facilitate comparisons, we dichotomized each outcome variable. Cut points for dichotomization were chosen based on the distribution of the data or according to the scoring of each instrument. High intensity of LBP was defined as NRS ≥ 7 []. This intensity of LBP cut-off was used to report frequencies of demographic variables at baseline and compared using Chi-squared tests.
To evaluate differences in recovery from the LBP problem, we evaluated the RMDQ score and use of pain medication across the four time points grouped by chronic disease variables. For the RMDQ score, we reported differences in mean score, with 95% confidence intervals and-values, from a linear regression model fitted with generalized estimating equation to account for repeated observations on the same individuals and the weighting procedure described below.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
NI jobs available to apply for today: product consultant to wet paint specialistFrom high-level software consultancy work at Kainos, Danish- and Spanish-speaking sales jobs at TTEC and Unicorn Group, and industrial painting at Caterpillar, there's plenty on offer on the jobs market
Lire la suite »
Cost of multi-million pound town centre redevelopment still could changeCost of multi-million pound town centre redevelopment still could change due to inflation
Lire la suite »
Incorporating sampling weights into robust estimation of Cox proportional hazards regression model, with illustration in the Multi-Ethnic Study of Atherosclerosis - BMC Medical Research MethodologyBackground Cox proportional hazards regression models are used to evaluate associations between exposures of interest and time-to-event outcomes in observational data. When exposures are measured on only a sample of participants, as they are in a case-cohort design, the sampling weights must be incorporated into the regression model to obtain unbiased estimating equations. Methods Robust Cox methods have been developed to better estimate associations when there are influential outliers in the exposure of interest, but these robust methods do not incorporate sampling weights. In this paper, we extend these robust methods, which already incorporate influence weights, so that they also accommodate sampling weights. Results Simulations illustrate that in the presence of influential outliers, the association estimate from the weighted robust method is closer to the true value than the estimate from traditional weighted Cox regression. As expected, in the absence of outliers, the use of robust methods yields a small loss of efficiency. Using data from a case-cohort study that is nested within the Multi-Ethnic Study of Atherosclerosis (MESA) longitudinal cohort study, we illustrate differences between traditional and robust weighted Cox association estimates for the relationships between immune cell traits and risk of stroke. Conclusions Robust weighted Cox regression methods are a new tool to analyze time-to-event data with sampling, e.g. case-cohort data, when exposures of interest contain outliers.
Lire la suite »
Many patients experience persistent pain after having Clade IIb mpoxIn a rapid communication published in the journal Eurosurveillance, researchers presented the interim results of a medium-term follow-up [three weeks to twenty weeks following MPOX virus infection follow-up study comprising patients attending sexual health clinics in Belgium.
Lire la suite »
Utilizing CRISPR to discover new therapy options for COPDContinuing our coverage of SLAS_org 2023, we speak to Ceri Wiggins, the Director of Functional genomics at AstraZeneca, about the many applications of CRISPR and its role in discovering new COPD therapies. Read more below!🧬👇
Lire la suite »